<sup>177</sup> Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

Amar U. Kishan(University of California, Los Angeles), Jérémie Calais(Molecular Theranostics (United States)), Zachary Ells(University of California, Los Angeles), Holly Wilhalme(Statistical Research (United States)), Vinícius Ludwig(University of California, Los Angeles), Johannes Czernin(University of California, Los Angeles), Minsong Cao(Ronald Reagan UCLA Medical Center), Luca Valle(University of California, Los Angeles), Daniel Karasik(University Hospitals of Cleveland), Ting Martin(University of Washington), Martin Allen-Auerbach(University of California, Los Angeles), Matthew B. Rettig(University of Southern California), Catherine Meyer(University of California, Los Angeles), Sophia Parmisano(University of California, Los Angeles), Kevin Flores(University of California, Los Angeles), Nicholas G. Nickols(VA Greater Los Angeles Healthcare System), T. Vincent Basehart(University of California, Los Angeles), Joanne B. Weidhaas(University of California, Los Angeles), Wayne Brisbane(University of California, Los Angeles), Magnus Dahlbom(University of California, Los Angeles), Michael L. Steinberg(University of California, Los Angeles), Michael Lauria(University of California, Los Angeles), Kristen M. McGreevy(Mira Dx (United States)), Donatello Telesca(University of California, Los Angeles), Leonard S. Marks(Urological Research Foundation), Javier Casillas(University of California, Los Angeles), Carol Felix(University of California, Los Angeles), Mariko Nakayama(University of California, Los Angeles), R. Nabong(University of California, Los Angeles), Paul C. Boutros(University of California, Los Angeles)
Journal of Clinical Oncology
November 12, 2025
Cited by 24


Related Papers